Max interacting protein 1: Loss of heterozygosity is frequent in desmoplastic melanoma

Modern Pathology

Volumn 12, Issue 4, 1999, Pages 344-350

  Rao, U N M ^a   Bakker, A ^a   Swalsky, P A ^a   Finkelstein, S D ^a,b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Desmoplastic melanoma; LOH microdissection; MXI1 gene

Indexed keywords

MAX INTERACTING PROTEIN 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME MICRODISSECTION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DNA POLYMORPHISM; FEMALE; GENE LOSS; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL;

ADULT; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; S100 PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032939214     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma) Cancer 1971; 28:914-36.
2. Carlson JA, Dickerson GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 28 cases. Cancer 1995;75:478-94.
3. Bruijin JA, Mihm MC, Barnhill RL. Desmoplastic melanoma. Histopathology 1992;20:197-206.
4. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants: a study of 45 cases. Am J Surg Pathol 1989;13:158-73.
5. Weinzweig N, Tuthill RJ, Yetman RJ. Desmoplastic malignant melanoma: a clinicopathologic review. Plast Reconstr Surg 1995;95:548-55.
6. Smithers BM, McLeod GR, Little JH. Desmoplastic neural transforming and neurotropic melanoma: a review of 45 cases. Aust N Z J Surg 1990;60:967-72.
7. Reiman HM, Goellner JR, Woods JE, Mixter RC. Desmoplastic melanoma of the head and neck. Cancer 1987;60:2269-74.
8. Kilpatrick SE, White WL, Browne JD. Desmoplastic melanoma of the oral mucosa: an under-recognized diagnostic pitfall. Cancer 1996;78:383-9.
9. Annstey A, McKee P, Jones EW. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br J Dermatol 1993;129:359-71.
10. Skelton HG, Smith KJ, Laskin WB, McCarthy WF, Gagnier JM, Graham JH, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995;32:717-25.
11. Walsh NMG, Roberts JT, Orr W, Simon GT. Desmoplastic malignant melanoma. Arch Pathol Lab Med 1988;112:922-7.
12. Fearns C, Dowdel EB. The desmoplastic response: induction of collagen synthesis by melanoma cells in vitro. Int J Cancer 1992;50:621-7.
13. Barsky SH, Gopalkrishna R. Increased invasion and spontaneous metastases of BLG melanoma with inhibition of desmoplastic response in C57 BL/6 mice. Cancer Res 1987;47: 1663-7.
14. Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol 1996;23:205-10.
15. Finkelstein SD, Przygodzki RM, Pricolo VE, Sakallah SA, Swalsky PA, Bakker A, et al. Prediction of biological aggressiveness in colorectal cancer by p53/k-ras-2 topographic genotyping. Mol Diagn 1996;1:5-28.
16. Kanbour-Shakir A, Kounelis S, Papadaki H, Price F, Edwards RP, Kelley JL, et al. Relationship of p53 genotype to second-look recurrence and survival in ovarian epithelial malignancy. Mol Diagn 1996;1:121-9.
17. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-3.
18. Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky PA, Finkelstein SD. Carcinosarcomas (malignant mixed Müllerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-7.
19. Albarosa R, Di Donato S, Finocchiaro G. Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3′ noncoding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. Hum Genet 1995;95:709-11.
20. Finkelstein SD, Sayegh R, Christensen S, Swalsky P. Genotypic classification of colorectal adenocarcinoma: biologic behavior correlates with k-ras-2 mutation type. Cancer 1993; 71:3827-38.
21. Dreesen JC, Bras M, Coonen E, Dumoulin JC, Evers JL, Geraedts JP. Allelic dropout caused by allele-speciflc amplification failure in single-cell PCR of the cystic fibrosis δ F508 deletion. J Assist Reprod Genet 1996;13:112-4.
22. Rechitsky S, Freidine M, Verlinsky Y, Strom CM. Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). J Assist Reprod Genet 1996;13:115-24.
23. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1 a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997;57:4905-12.
24. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993;53:936-42.
25. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p and evidence for genetic heterogeneity. Am J Hum Genet 1994;54:489-96.
26. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:22-6.
27. Albino AP. Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995;7:162-9.
28. Piepkorn MW. Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 1994;31:1022-39.
29. Matsuta M, Matsuta M, Kon S, Thompson C, Le Boit PE, Weier H-U, et al. Interphase cytogenetics of melanocytic neoplasms: numerical aberrations of chromosomes can be detected in interphase nuclei using centromeric DNA probes. J Cutan Pathol 1994;21:1-6.
30. Walker GJ, Palmer JM, Walters MK, Hayward NK. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosom Cancer 1995;12:134-41.
31. Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP, et al. Cytogenetics of 158 patients with regional or disseminated melanoma: subset analysis of near diploid and simple karyotypes. Cancer Genet Cytogenet 1995;83:93-104.
32. Heim S, Mittelman F. Tumors of the skin. In: Heim S, Mittleman F, editors. Cancer cytogenetics. 2nd ed. New York: Wiley; 1995. p. 469-75.
33. Parmiter AH, Balaban G, Clark WH Jr, Nowel PC. Possible involvement of the chromosome region 10q24-q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 1988;30:313-7.
34. Grammatico P, Modesti A, Steindl K, Scarpa S, Heouaine A, Picardo M, et al. Lentigo maligna: cytogenetic, ultrastructural, and phenotypic characterization of a primary cell culture. Cancer Genet Cytogenet 1992;60:141-6.
35. Herbst RA, Weiss J, Ehnis AA, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10pter in malignant melanoma progression. Cancer Res 1994;54:3111-4.
36. Isshiki K, Elder DE, Guerry D, Linnenbach AJ. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosom Cancer 1993;8:178-84.
37. Albarosa R, Di Donato S, Finnocchiaro G. Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3′ noncoding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. Hum Genet 1994;95:709-11.